Ocular Therapeutix, Inc.
US ˙ NasdaqGM ˙ US67576A1007

SecurityOCUL / Ocular Therapeutix, Inc.
InstitutionExodusPoint Capital Management, LP
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
ExodusPoint Capital Management, LP closes position in OCUL / Ocular Therapeutix, Inc.

On February 17, 2026 - ExodusPoint Capital Management, LP filed a 13F-HR form disclosing ownership of 0 shares of Ocular Therapeutix, Inc. (US:OCUL) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 163,132 shares of Ocular Therapeutix, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-17 2025-12-31 13F OCULAR THERAPEUTIX COM 67576A100 0 -163,132 -100.00 0 -100.00
2025-11-14 2025-09-30 13F OCULAR THERAPEUTIX COM 67576A100 163,132 163,132 1,907 0.0195
2025-08-13 2025-06-30 13F OCULAR THERAPEUTIX COM 67576A100 0 -96,185 -100.00 0 0.0000
2025-05-14 2025-03-31 13F OCULAR THERAPEUTIX COM 67576A100 96,185 96,185 1 0.0070
2024-02-13 2023-12-31 13F OCULAR THERAPEUTIX COM 67576A100 0 -98,422 -100.00 0 0.0000
2023-11-13 2023-09-30 13F OCULAR THERAPEUTIX COM 67576A100 98,422 98,422 0 0.0030
2023-02-13 2022-12-31 13F OCULAR THERAPEUTIX COM 67576A100 0 -13,402 -100.00 0 -100.00
2022-11-10 2022-09-30 13F OCULAR THERAPEUTIX COM 67576A100 13,402 13,402 56 0.0007
2022-08-20 2022-06-30 13F OCULAR THERAPEUTIX COM 67576A100 0 -11,306 -100.00 0 -100.00
2022-05-13 2022-03-31 13F OCULAR THERAPEUTIX COM 67576A100 11,306 11,306 56 0.0007
2022-02-11 2021-12-31 13F OCULAR THERAPEUTIX COM 67576A100 0 -13,662 -100.00 0 -100.00
2021-11-15 2021-09-30 13F OCULAR THERAPEUTIX COM 67576A100 13,662 3,561 35.25 137 -4.20 0.0018
2021-08-16 2021-06-30 13F OCULAR THERAPEUTIX COM 67576A100 10,101 10,101 143 0.0016
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.